PARIS--(BUSINESS WIRE)-- EOS imaging (Paris:EOSI)(Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced the sale of the third EOS system into the Nemours Children’s Health System. The EOS system was ordered by Nemours Children’s Hospital in Orlando, Florida, one of the two flagship hospitals in the network.
Nemours is a pediatric health system dedicated to life-changing medical care and research, helping children grow up healthy, advocating for kids nationally and training tomorrow’s pediatric experts. The first two sales of the EOS system in the Nemours Children’s Health System were to Nemours/Alfred I. duPont Hospital for Children in Wilmington, Delaware; and Nemours Children’s Specialty Care in Jacksonville, Florida.
“We've been using EOS imaging at duPont Hospital for Children for just over five years. It offers so many benefits for our patients, including substantially less radiation exposure than existing x-ray equipment and better quality images of the entire spine and limbs in a standing position. The process takes just seconds and allows physicians the ability to study the spine in three dimensions, so we can better classify and treat complex deformities and provide our patients with better outcomes,” says Suken A. Shah, MD, Division Chief, Nemours Spine and Scoliosis Center.
Marie Meynadier, CEO of EOS imaging, said, “Nemours is dedicated to providing advanced care to children, and we are pleased that they are adopting our solution as part of their standard of care for patients in their network. Nemours has been at the forefront of advocating low dose 3D imaging, and the Wilmington location was also recently the first in the U.S. to use our new EOS chair for non-ambulatory patient imaging. We look forward to serving their health professionals and patients for better care.”
For more information, please visit www.eos-imaging.com.
EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
About EOS imaging
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2016 revenues of €30.8 million and employs 132 people at December 2016, including an R&D team of 43 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.